Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson : J&J warns of hit from generic drugs in third quarter, shares fall

07/16/2019 | 12:20pm EDT
The Johnson & Johnson logo is displayed on a screen on the floor of the NYSE in New York

(Reuters) - Johnson & Johnson on Tuesday boosted its 2019 sales forecast amid robust demand for its cancer drugs, but warned that competition from generic and copycat drugs could impact its third-quarter results, sending shares down 1.4% in noon trading.

While J&J's pharmaceuticals unit has in recent years cushioned the impact of relatively slow growth in the company's medical device and consumer units, some of its older drugs have been hurt by competition from cheaper copies.

"We expect the largest impacts from generics and biosimilars for the year in our pharmaceutical business to occur in the third quarter," Chief Financial Officer Joseph Wolk said on a conference call.

Once a drug begins facing competition from multiple generic versions, it can quickly lose more than 80% of sales.

Sales of prostate cancer treatment Zytiga fell 23% in the quarter, hurt by generic copies, and sales of J&J's blockbuster arthritis drug Remicade fell 16%, impacted by biosimilar rivals.

Also weighing on the stock was the company's decision to not raise its full-year earnings forecast, even as sales across all its business units largely beat analysts' estimates.

"We expect questions on the maintained earnings per share guidance but we point to the continued-to-be-improving strength across its franchises despite pharma headwinds," said BMO Capital Markets analyst Joanne Wuensch.

Pharmaceutical sales in the quarter rose 1.7% to $10.53 billion (£8.46 billion), above analysts' estimates of $10.27 billion, according to three analysts polled by Refinitiv.

(For a
graphic on 'J&J's newer drugs fuel pharmaceuticals unit sales', click

The company raised its 2019 forecast for operational sales, which excludes the impact of currency fluctuations, to a range of $82.4 billion to $83.2 billion, from a prior range of $82 billion to $82.8 billion.

J&J took a $190 million charge in the quarter related to litigation over its talc products. Executives on the conference call said this only related to defence costs and did not include liability payments.

The company faces lawsuits https://www.reuters.com/article/us-johnson-johnson-talc-probe/johnson-johnson-faces-criminal-probe-related-to-baby-powder-bloomberg-idUSKCN1U726J involving over 14,000 plaintiffs who allege use of its talc products, including Baby Powder, caused cancer https://www.reuters.com/investigates/special-report/johnsonandjohnson-cancer. J&J repeatedly has claimed its talc products are safe and that decades of studies have shown them to be asbestos-free and that they do not cause cancer.

Excluding items, the company earned $2.58 per share, beating analysts' expectations for $2.46 per share, according to IBES data from Refinitiv.

Sales fell 1.3% to $20.56 billion as growth in the international market helped counter falling sales in the United States. Analysts were expecting sales of $20.29 billion.

(For a
graphic on 'J&J's newer drugs fuel pharmaceuticals unit sales', clickhttps://tmsnrt.rs/2kbwYl2

(For an interactive
graphic on 'J&J's newer drugs fuel pharmaceuticals unit sales', clickhttps://tmsnrt.rs/2k439mJ/p>

(Reporting by Manas Mishra and Manojna Maddipatla in Bengaluru and Julie Steenhuysen in Chicago; Editing by Bernadette Baum)

By Manas Mishra and Manojna Maddipatla


ę Reuters 2019
All news about JOHNSON & JOHNSON
04:19pJOHNSON & JOHNSON : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION ..
AQ
01:01pEMERGENT BIOSOLUTIONS : resumes COVID-19 vaccine production
AQ
12:06pJOHNSON & JOHNSON : SA to Soon Administer Over 300,000 Covid-19 Vaccines a Day
AQ
11:16aJOHNSON & JOHNSON : Women Cancer Victims Opposed to Johnson & Johnson's 'Texas T..
PR
11:06aJOHNSON & JOHNSON : and Vaccine Gets Approval
AQ
10:04aJOHNSON & JOHNSON : Statement on U.S. FDA Approval of Shelf Life Extension for C..
AQ
09:33aBIOHIT OYJ : Appoints New CEO
MT
05:44aLABORATORIO REIG JOFRE S A : Reig Jofre Delays Manufacturing of Johnson & Johnso..
MT
02:01aBIOHIT OYJ : Päivi Siltala new CEO of Biohit Oyj
AQ
12:08aJOHNSON & JOHNSON : What is a COVID-19 vaccine 'breakthrough' case?
AQ
More news
Financials (USD)
Sales 2021 94 452 M - -
Net income 2021 22 808 M - -
Net Debt 2021 853 M - -
P/E ratio 2021 20,2x
Yield 2021 2,41%
Capitalization 453 B 453 B -
EV / Sales 2021 4,81x
EV / Sales 2022 4,59x
Nbr of Employees 134 500
Free-Float 84,3%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | MarketScreener
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Last Close Price 172,18 $
Average target price 184,35 $
Spread / Average Target 7,07%
EPS Revisions
Managers and Directors
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON9.40%453 418
ROCHE HOLDING AG12.49%332 374
PFIZER, INC.18.04%243 220
ELI LILLY AND COMPANY46.00%224 084
NOVARTIS AG0.39%223 750
ABBVIE INC.10.64%209 386